Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00LAA
|
|||
| Former ID |
DIB003382
|
|||
| Drug Name |
VA-118020
|
|||
| Synonyms |
KKI; FE-999155; Kallikrein 1 inhibitor (oral, respiratory disorders), Vantia
Click to Show/Hide
|
|||
| Indication | Respiratory disease [ICD-11: CB40] | Investigative | [1] | |
| Company |
Vantia Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue kallikrein (KLK1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Endocrine and other factor-regulated calcium reabsorption | |||
| Reactome | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||
| WikiPathways | Blood Clotting Cascade | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2865). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.